You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華潤醫藥(03320.HK)旗下科技創新平臺打造AI驅動藥物研發全鏈條
阿思達克 07-07 12:21
華潤醫藥(03320.HK)宣佈,集團旗下北京雙鶴潤創科技有限公司在創新藥物研發領域提出創新解決方案,以「人工智能驅動的創新藥物開發與概念驗證平臺」爲核心,整合了國有企業全產業鏈的資源和人工智能技術的優勢,爲生物醫藥創新提供從分子設計到商業落地的一站式服務,開闢了科技成果轉化的新途徑。 該平臺以「技術+資源」爲雙核驅動,構建了四大核心能力:通過人工智能分子設計(AI)技術,重塑了研發流程,實現了靶點篩選、分子優化、成藥性預測的全流程智能化。平臺自主搭建了六大技術平臺,涵蓋創新藥分子設計、藥物化學、藥理毒理等,支持腫瘤、代謝、兒科等領域的藥物開發。依託平臺化能力,多個1類新藥快速推進至臨牀階段,顯着減少了對外部CRO(合同研究組織)的依賴。其中,核心研發項目Fascin蛋白抑制劑爲全球首款針對腫瘤轉移的創新藥,依託六大技術平臺能力,僅用3年時間便推至Ⅱ期臨牀研究。 AI驅動的項目研發週期顯着縮短,多個研發管線進展迅速,體現了集團研發效率的突破。與北京安貞醫院、兒童醫院、兒研所等合作開發的降壓藥、兒童白血病、兒童呼吸窘迫症用藥等已上市;抗腫瘤轉移藥、眼科某領域罕見病藥物等已進入臨牀階段,充分展現了成果轉化的加速。 集團旗下有關AI製藥時代的全鏈條服務平臺,隨着AI與生物技術的深度融合,有望成爲培育醫藥新質生產力的關鍵引擎,爲集團的高質量發展儲備動力勢能。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account